Platelet Reconstitution after Allogeneic hematopoietic stem cell transplantation
Conditions
Interventions
Romiplostim intervention group:Starting 4 days after transplantation, administer Romosozumab 250 µg per dose subcutaneously, once a week, until 60 days after transplantation.
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Participants provided voluntary, written informed consent prior to enrollment and demonstrated consistent adherence to the study protocol, including full cooperation with all scheduled follow-up assessments. 2.Participants met established clinical indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT), fulfilled pre-transplant eligibility criteria based on comprehensive physical examination and laboratory evaluation, and were scheduled to undergo allo-HSCT at the First Affiliated Hospital of Xi’an Jiaotong University. 3.Pre-transplant peripheral blood platelet count was =50 × 10?/L, and bone marrow examination confirmed a normal megakaryocyte count. 4. Age between 18 and 70 (inclusive);
Exclusion criteria
Exclusion criteria: 1.Patients diagnosed with primary or secondary myelofibrosis, as well as those with acute leukemia transformed from myelofibrosis. 2.Patients with antiphospholipid syndrome or hereditary thrombophilia before transplantation, and those whose researchers judge that the risk of thrombosis after transplantation is high; 3.Other situations where researchers determine that the patients are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet reconstitution time; | — |
Countries
China
Contacts
Public ContactRen Juan
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed